This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biogen's New Multiple Sclerosis Pill Sales: $192 Million

Stocks in this article: BIIB

BIIB Chart BIIB data by YCharts

Updated with new information

CAMBRIDGE, Mass. ( TheStreet) -- Biogen Idec (BIIB) reported $192 million in second-quarter sales of its new multiple sclerosis pill Tecfidera and raised earnings guidance for the rest of the year.

Investors had high expectations for Tecfidera going into this morning's earnings report -- looking for end-user sales of at least $90 million in the first three months of the drug's U.S. launch.

Biogen appears to have given investors what they wanted. Total Tecfidera sales to patients -- a true measure of demand for the drug -- were $110 million. The company recorded another $82 million in Tecfidera revenue from wholesaler inventory stocking.

Helped along by the strong Tecfidera launch, Biogen raised guidance for 2013 adjusted earnings to a range of $8.25 to $8.50 per share, above the current consensus of $8.20 per share.

Biogen said it expects to post revenue growth for 2013 in the range of 22 percent to 23 percent, above the 20 percent earnings growth expected by analysts.

Still, Biogen shares were trading flat to slightly down Thursday largely due to high expectations already priced into the stock, plus lingering concerns about the company's ability to launch Tecfidera in Europe on time.

On a conference call, Biogen executives said Tecfidera exclusivity discussions in Europe were taking longer than expected and that any revenue generated by the drug in Europe this year would not be meaningful. Some investors took this to mean that Biogen may not launch the drug in Europe this year, as expected, although the company did not come out and say that specifically.

Back in the U.S., Biogen said the rate at which new multiple sclerosis patients start on Tecfidera may "moderate" in the next quarters because of pent-up demand for the drug at its launch.

For the quarter ended June 30, Biogen reported adjusted net income of $549 million, or $2.30 per share, up 25 percent and 26 percent from the prior year's quarter, respectively.

Revenue in the second quarter totaled $1.7 billion, an 21 percent increase over from the year-ago quarter.

Biogen shares closed Wednesday at $226.61, ahead of the earnings announcement.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs